The global cell and gene therapy market size was valued at USD 27.38 billion in 2025 and is projected to grow from USD 33.85 billion in 2026 to USD 184.60 billion by 2034, registering a CAGR of 23.62% during the forecast period from 2026 to 2034. North America dominated the cell and gene therapy market with a market share of 46.8% in 2025.
Cell and gene therapy includes advanced medical treatments that modify or replace genes or use living cells to treat, prevent, or potentially cure diseases. These therapies are widely used for genetic disorders, certain cancers, and rare diseases by targeting the root cause of illness. Demand is growing due to rapid advances in biotechnology, increasing clinical research, and rising investments in personalized and regenerative medicine.
Download a Free Sample To learn more about this report,
Increasing Adoption of In Vivo Gene Editing Approaches
The cell and gene therapy market is shifting toward in vivo approaches that modify or correct genetic material directly inside the patient's body. Compared with ex vivo approaches that require cells to be collected, modified, and reinfused, in vivo technologies can potentially simplify treatment workflows and broaden access to genetic medicines. Advances in delivery systems and genome-editing technologies are increasing development activity around these approaches.
In December 2023, the U.S. Food and Drug Administration approved the first CRISPR/Cas9-based gene therapies for sickle cell disease, establishing a major regulatory milestone for gene-editing medicines.
Growing Development of Allogeneic Cell Therapies
The cell therapy market is increasingly exploring allogeneic products manufactured from donor cells rather than relying exclusively on patient-specific autologous cells. Allogeneic approaches can potentially support standardized manufacturing and the production of multiple treatment doses from a common cell source. This is encouraging research into off-the-shelf cell therapies for oncology and other therapeutic applications.
In February 2025, the U.S. Food and Drug Administration issued guidance addressing human gene therapy products incorporating genome-editing technologies, reflecting continued regulatory development as advanced cell and gene therapy platforms progress toward clinical use.
Growing Burden of Cancer and Genetic Disorders Supports Demand for Advanced Therapies
The large patient population affected by cancer and inherited genetic disorders creates a substantial need for treatments capable of addressing underlying disease mechanisms. Cell and gene therapies can introduce functional genetic material, modify disease-associated genes, or use engineered cells to produce targeted therapeutic effects. Increasing clinical research and diagnosis of severe diseases therefore support continued development and demand for these therapies.
In February 2026, the World Health Organization reported that cancer caused nearly 10 million deaths globally in 2022, underscoring the substantial disease burden driving the development of new treatment modalities.
High Manufacturing Costs Limit Commercial Accessibility
Cell and gene therapies can require specialized facilities, viral vectors or other delivery systems, highly controlled cell-processing workflows, and extensive quality testing. These requirements make manufacturing considerably more complex than conventional pharmaceutical production and can result in high treatment costs. The economic burden can restrict reimbursement and limit access even after regulatory approval.
In January 2025, the U.S. Food and Drug Administration identified manufacturing complexity, process consistency, and scalability as important considerations in the development and commercialization of cell and gene therapy products.
Expansion of Cell and Gene Therapies Into Rare Diseases Creates New Market Potential
Rare diseases represent an important opportunity because many have limited or no effective disease-modifying treatments. Gene replacement, gene editing, and engineered cell therapies can potentially address specific molecular causes of rare disorders rather than only managing symptoms. Growing regulatory pathways and clinical development activity are encouraging companies to target increasingly diverse rare-disease indications.
In March 2025, the U.S. Food and Drug Administration approved a gene therapy for cerebral adrenoleukodystrophy, expanding the number of rare diseases with an approved gene-based treatment option.
Long-Term Safety Monitoring Complicates Cell and Gene Therapy Development
Because cell and gene therapies can produce persistent biological changes, patients may require long-term monitoring after treatment. Potential concerns include immune responses, off-target genetic effects, insertional risks, and delayed adverse events depending on the therapeutic platform. Developers and healthcare providers must therefore establish extended follow-up programs that can increase clinical complexity and development requirements.
In January 2025, the U.S. Food and Drug Administration continued to require long-term follow-up considerations for certain human gene therapy products because delayed adverse events may occur years after administration.
CAR-T Cell Therapy Segment Dominated the Market with 22.4% Share in 2025
The CAR-T cell therapy segment dominated the global cell and gene therapy market with a 22.4% share in 2025. CAR-T therapy has become one of the most successful cell-based treatments for blood cancers because it delivers highly targeted immune responses and has shown promising long-term clinical outcomes. Increasing regulatory approvals and expanding clinical applications continue to strengthen the segment's leading position.
The cell therapy, gene therapy, CAR-NK, B-cell therapy, and other therapy segments are also witnessing steady growth as researchers develop advanced treatments for cancer, rare diseases, and genetic disorders. Cell therapy is gaining wider adoption for regenerative medicine, while gene therapy is expanding as it offers the potential to treat diseases at the genetic level. CAR-NK therapies are attracting attention due to their promising safety profile, and B-cell therapies continue to support treatment for hematological conditions.
Within the CAR-T segment, autologous CAR-T remains widely used because it uses the patient's own immune cells to reduce the risk of rejection. The allogeneic CAR-T segment is growing rapidly as manufacturers develop off-the-shelf therapies that can improve treatment availability and reduce manufacturing time. Within gene therapy, viral vectors continue to dominate delivery systems, with adeno-associated virus (AAV) and lentiviral vectors being widely used for targeted gene delivery, while other vector technologies continue to evolve through ongoing research and innovation.
Request Customizationto receive a tailored report.
Oncology Segment Dominated the Market with 48.7% Share in 2025
The oncology segment dominated the global cell and gene therapy market with a 48.7% share in 2025. Cell and gene therapies are increasingly used in cancer treatment because they offer highly targeted approaches that improve treatment outcomes while reducing damage to healthy tissues. The growing number of cancer clinical trials and product approvals continues to support this segment's leading position.
The immunology, musculoskeletal, dermatology, and neurology segments are also growing steadily as advanced therapies are being developed for autoimmune disorders, tissue repair, skin diseases, and neurological conditions. Researchers continue to expand the use of gene editing and regenerative medicine across these therapeutic areas.
The others segment also continues to expand as cell and gene therapies are investigated for rare diseases, inherited disorders, and additional chronic conditions. Continuous innovation and increasing investment in regenerative medicine are expected to support growth across all application areas.
Biopharmaceutical & Biotechnology Companies Segment Dominated the Market with 49.5% Share in 2025
The biopharmaceutical & biotechnology companies segment dominated the global cell and gene therapy market with a 49.5% share in 2025. These companies are leading the development of innovative cell and gene therapies through significant investments in research, clinical trials, and commercialization. Their strong focus on precision medicine and advanced biologics continues to drive market growth.
The pharmaceutical companies segment is also growing steadily as major drug manufacturers expand their regenerative medicine portfolios through strategic partnerships, acquisitions, and internal research programs. Their global manufacturing capabilities and regulatory expertise are helping accelerate the commercialization of advanced therapies.
The CDMOs/CMOs segment is expanding rapidly as therapy developers increasingly outsource manufacturing to specialized organizations with expertise in cell processing, viral vector production, and quality control. The others segment also contributes to market growth through academic institutions, research organizations, and emerging biotechnology companies that continue to advance innovation in cell and gene therapy.
Speak to an Analystto discuss market opportunities.
North America cell and gene therapy market accounted for 46.8% of the global market, reaching USD 12.81 billion in 2025, and is projected to grow at a CAGR of 17.94% during the forecast period. The market is growing rapidly because of increasing investment in advanced biologics, strong clinical trial activity, and rising approvals for cell and gene therapies. Well-established biotechnology companies and supportive regulatory frameworks are also driving regional growth.
The U.S. market was valued at USD 10.89 billion in 2025, making it the largest contributor in North America. Strong investment in biotechnology, increasing clinical research, and growing adoption of advanced therapies for cancer and rare diseases continue to drive market growth.
Canada's market reached USD 1.92 billion in 2025. Expanding life science research, increasing government support for biotechnology, and rising clinical trial activity continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe cell and gene therapy market accounted for 27.4% of the global market, reaching USD 7.50 billion in 2025, and is expected to register a CAGR of 18.16% during the forecast period. Rising investment in precision medicine, growing biotechnology innovation, and increasing collaboration between research institutes and pharmaceutical companies are supporting market growth. The region is also expanding manufacturing capacity for advanced therapies.
Germany's market accounted for USD 2.18 billion in 2025. Strong biotechnology research, increasing clinical development, and growing investment in advanced therapy manufacturing continue to support market growth.
The UK market was valued at USD 1.50 billion in 2025. Expanding research in regenerative medicine, increasing clinical trials, and strong government support for life sciences continue to contribute to market growth.
Asia Pacific cell and gene therapy market accounted for 18.6% of the global market, valued at USD 5.09 billion in 2025, and is projected to register a CAGR of 21.48% during the forecast period. Growing biotechnology investments, expanding healthcare infrastructure, and increasing research into regenerative medicine are driving market growth across the region. Government funding and rising demand for innovative treatments are also creating strong opportunities.
Japan's market generated USD 0.92 billion in 2025. Strong research capabilities, supportive regulatory policies, and increasing development of regenerative therapies continue to support market growth.
China's market accounted for USD 2.65 billion in 2025, representing the largest share within Asia Pacific. Rapid expansion of biotechnology companies, increasing clinical trials, and significant investment in advanced healthcare technologies continue to drive market growth.
Latin America cell and gene therapy market accounted for 4.2% of the global market, reaching USD 1.15 billion in 2025, and is projected to grow at a CAGR of 16.87% during the forecast period. Improving healthcare infrastructure, increasing biotechnology research, and growing access to advanced therapies are supporting market growth across the region.
Brazil's market reached USD 0.59 billion in 2025. Rising investment in healthcare research, expanding biotechnology capabilities, and increasing collaboration with global pharmaceutical companies continue to create growth opportunities.
Middle East & Africa cell and gene therapy market accounted for 3% of the global market, totaling USD 0.82 billion in 2025, and is anticipated to grow at a CAGR of 15.92% during the forecast period. Increasing investment in healthcare innovation, expanding biotechnology infrastructure, and growing focus on advanced treatment options are supporting market growth across the region.
The UAE market was valued at USD 0.30 billion in 2025. Government investment in advanced healthcare, growing biotechnology initiatives, and increasing adoption of precision medicine continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com